John McKay, DO
Hematology & Oncology · Winston Salem, NCNPI 1841671914
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,453 of the $22,099 with a category attached, or 88.0%. Johnson & Johnson accounts for 72.9% of it on its own, with 8 other manufacturers making up the rest.
Across 28 payments — averaging $789.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$16K
- E.r. Squibb & Sons, L.L.C.$4K
- Sanofi$1K
- Adaptive Biotechnologies Corporation$130
- Pfizer$123
- Incyte Corporation$99
- plus $168 from 3 others
Across 476 payments — averaging $6073.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.2M
- AbbVie$1M
- Regeneron$611K
- Takeda Pharmaceuticals U.S.A., Inc.$27K
- Bristol Myers Squibb$20K
- E.r. Squibb & Sons, L.L.C.$6K
What the payments were for
- Consulting fees$19,45388%
- Travel & lodging$1,2946%
- Food & beverage$1,2316%
- Education$1221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $16,104 |
| E.r. Squibb & Sons, L.L.C. | 5 | $4,115 |
| Sanofi | 5 | $1,361 |
| Adaptive Biotechnologies Corporation | 1 | $130 |
| Pfizer | 1 | $123 |
| Incyte Corporation | 1 | $99 |
| Gilead | 1 | $91 |
| Biolinerx USA, Inc. | 1 | $50 |
| Recordati_rare_diseases_inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,099 in reported general payments places this provider in the 80th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 20 | $282,420 |
| Acyclovir | 170 | $1,656 |
| Gabapentin | 36 | $912 |
| Oxycodone Hcl | 17 | $262 |
| Dexamethasone | 19 | $242 |
| Omeprazole | 18 | $226 |
| Potassium Chloride | 19 | $218 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 29 | $189 |
| Duloxetine Hcl | 13 | $136 |
| Ondansetron Hcl | 15 | $72 |
| Levothyroxine Sodium | 13 | $65 |
| Prednisone | 18 | $54 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Winston Salem
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Caio Max Rocha LimaWinston Salem$110K
- Timothy PardeeWinston Salem$68K
- Leon Bernal-MizrachiWinston Salem$62K
- Matthew WieduwiltWinston Salem$36K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.